[The evaluation of prognostic value of cyclin B1 expression in patients with resected non-small-cell lung cancer stage I-IIIA--preliminary report].
Lung cancer is a leading cause of cancer death in the majority of developed countries and in Poland. THE AIM of this study was to evaluate the prognostic significance of cyclin B1 expression in primary, resected stage I-IIIA non-small cell lung cancer. The expression of cyclin BI was investigated in the paraffin-embedded tumor tissues of 71 patients (53 male and 18 female, aged 59.27 + 8.50 years), using a mouse monoclonal antibody to cyclin B1. In all patients the 24 month survival was determined. Thirty eight (54%) patients survived and 33 (46%) died. Positive expression of cyclin B1 was documented in 6 (8.5%) tumor tissue specimens. Only cytoplasmatic staining was revealed. The prognostic values of cyclin B1 expression were presented in all examined patients and in patients with squamous cell lung cancer, adenocarcinoma and separately in every stage of disease. Any correlations between cyclin B1 expression and survival of patients were not confirmed in all examined groups. In examined groups we did not reveal neither the prognostic value of cyclin B1 expression in patients with resected nonsmall cell lung cancer nor the correlations between cyclin B1 expression and neoadjuvant chemotherapy. More studies are expected in the future.